Vi­iV, Pfiz­er and Roche lead list for phar­ma rep­u­ta­tion ranked by pa­tient group, an­nu­al sur­vey finds

Pa­tient groups’ view of the phar­ma in­dus­try around the world is im­prov­ing, ac­cord­ing to an an­nu­al sur­vey pub­lished on Tues­day. Fifty-nine per­cent of pa­tient groups agreed that the phar­ma in­dus­try’s cor­po­rate rep­u­ta­tion is “ex­cel­lent” or “good,” com­pared to just 50% the year be­fore, ac­cord­ing to Pa­tientView’s an­nu­al on­line cor­po­rate rep­u­ta­tion sur­vey.

Top­ping the list at No. 1 is HIV-spe­cial­ty drug­mak­er Vi­iV Health­care which is ma­jor­i­ty-owned by Glax­o­SmithK­line with Pfiz­er and Sh­iono­gi share­hold­ers. Fol­low­ing Vi­iV is Pfiz­er in the sec­ond spot, then Roche and Genen­tech rank to­geth­er at No. 3. Gilead and John­son & John­son’s Janssen fol­low them, round­ing out the top five.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.